Fig. 2From: Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapyTrends in absolute NLR and TLR after [166Ho]-radioembolization, with a significant peak 3 weeks after treatment. FU follow-upBack to article page